Amendment Statement of Principles concerning immune thrombocytopaenia (Reasonable Hypothesis) (No. 57 of 2022) (Cth)
Amendment Statement of Principles
concerning
IMMUNE THROMBOCYTOPAENIA
(Reasonable Hypothesis)
(No. 57 of 2022)
The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.
Dated 29 April 2022
| The Common Seal of the |
| Professor Terence Campbell AM |
Contents
1Name........................................................................................................................................... 3
2Commencement........................................................................................................................ 3
3Authority..................................................................................................................................... 3
4Amendment............................................................................................................................... 3
Name
This is the Amendment Statement of Principles concerning immune thrombocytopaenia (Reasonable Hypothesis) (No. 57 of 2022).
Commencement
This instrument commences on 30 May 2022.
Authority
This instrument is made under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.
Amendment
The Statement of Principles concerning immune thrombocytopaenia (Reasonable Hypothesis) (No. 63 of 2017) (Federal Register of Legislation No. F2017L01448) is amended in the following manner:
Section Amendment Schedule 1 – Dictionary Before paragraph (a) of the "specified list of vaccines" insert:
(aa) coronavirus disease 2019 (COVID-19) vaccine;
Schedule 1 – Dictionary After paragraph (o) of the "specified list of viral infections" insert:
(oa) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);
Schedule 1 – Dictionary Insert the following note to the definition of "specified list of viral infections":
Note: SARS-CoV-2 is the virus which causes coronavirus disease 2019 (COVID-19).
0
0
0